# Acomhal Research

Source: https://onco.cc/companies/acomhal-research/  
OnCo record `acomhal-research` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Acomhal Research is a Virginia company developing a peptide drug aimed at the treatment-resistant cells that let cancers such as glioblastoma grow back after treatment.

## Summary

Acomhal Research, Inc. develops a patented mimetic peptide derived from connexin 43 (Cx43) as an add-on therapy against chemotherapy-resistant cancer cells, with programmes listed in glioblastoma, breast, colon, pancreatic and lung cancer and melanoma. The company reports that the peptide eliminated chemotherapy-resistant glioblastoma cells, including glioma stem cells, in laboratory and animal studies. A 2026 National Cancer Institute STTR award funds alphavirus vector-mediated expression of the Cx43 mimetic peptide, named JM2 in the award abstract, for glioblastoma.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: Acomhal Research, Inc.
- HQ: Roanoke, VA
- Type: biotech
- Website: https://acomhal.com/

## Notes

- Company website (home and glioblastoma pages) and the NIH RePORTER record read on 4 November 2026. The website does not name its peptide; the name JM2 is from the award abstract.

## Sources

- Official website: https://acomhal.com/
- Glioblastoma programme: https://acomhal.com/glioblastoma/
- NIH RePORTER: award 1R41CA306619-01A1: https://reporter.nih.gov/project-details/11409740

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [JM2](https://onco.cc/drugs/jm2/)

---
JSON: https://onco.cc/api/v1/entities/acomhal-research.json